NOW FDA APPROVED
Introducing VIZIMPRO, a First-Line Treatment for Patients with NSCLC that has Spread to Other Parts of the Body and has Certain Mutations in EGFR (an Exon 19 Deletion or the L858R Substitution in Exon 21)
VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).
VIZIMPRO is used as a first treatment if tumors have certain types of abnormal epidermal growth factor receptor (EGFR) gene(s).
Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.